Stray Dog

Hims & Hers Q3: revenue up 49%, but subscribers and margin fall

  • Mixed: Revenue rose 49%, but from higher spend per customer and acquisitions, not user growth.
  • Bad news: Subscribers fell by about 100,000 from Q2, hitting the premise behind the moat.
  • Bad news: Gross margin was 57% against 74% a year earlier, and full-year adjusted EBITDA guidance was cut.
Read the full notes

The investment case warning (⚠️) is stronger. The 49% revenue growth comes from fewer customers paying more (a higher average order value for branded weight-loss drugs, plus consolidated overseas acquisitions), not from user growth. A fall of about 100,000 subscribers quarter on quarter hits the premise behind the moat (users plus accumulated health data).

Read more

Gross margin of 57% (74% a year earlier), cash flow and profit guidance have all weakened together. Huberman's board seat is brand marketing plus a related-party transaction, and it weakens board independence. The next test: whether subscribers return to quarter-on-quarter growth in Q1 2027, and whether gross margin holds above 57%.

Key evidence

  • Q3 revenue was $890 million, up 49% YoY (Q2: +38%), accelerating for a second quarter. US revenue was $657 million (+21%) and overseas $233 million (+321%). The overseas share rose from 17% in Q2 to 26%
  • Subscribers were 2.788 million, about 100,000 fewer than Q2's 2.891 million. YoY growth slowed from 19% to 13%. Monthly revenue per subscriber was $105 (Q2: $92)
  • Gross margin was 57% (Q2: 64%, a year earlier: 74%). Operating loss was $66.1 million and net loss $33 million (a year earlier: net profit of $15.8 million)
  • Operating cash flow was $65.4 million (a year earlier: $149 million) and free cash flow $26 million (a year earlier: $79.4 million)
  • Full-year revenue guidance was narrowed from $3.1-3.3 billion to $3.13-3.15 billion. Full-year adjusted EBITDA guidance was cut from $275-325 million to $257-277 million. Q4 revenue guidance of $875-895 million is roughly flat quarter on quarter
  • Management: the subscriber decline was mainly due to a deliberate cut in weight-loss marketing. It plans to step up spending in Q1 2027, once Eli Lilly's Zepbound and Foundayo are listed and multi-month subscriptions are ready
Show 6 more
  • New products: injectable and oral testosterone replacement therapy (the first controlled-substance category). FDA rules on peptides and similar products are expected to be clear within weeks
  • Overseas revenue is expected to reach an annualised run rate of more than $1 billion in 2027, focused on the UK, Germany and Australia
  • Balance sheet: convertible bonds of $1.37 billion, $563 million of acquisition payments still due, and goodwill of $1.11 billion (start of the year: $278 million)
  • Receivables were $428 million (start of the year: $32 million) and payables $516 million (start of the year: $143 million). Operating cash flow is clearly being propped up by payables
  • Shareholders' equity was $355 million (start of the year: $541 million)
  • Huberman was appointed on 4 Nov, taking the board from 9 to 10 members, as a non-independent director. His two-year advisory agreement pays $3.5 million a year in cash plus up to $1 million a year for short video ads. Scicomm Media has a three-year podcast advertising deal worth $5 million a year (his personal interest is about $2.1 million a year)

Catalysts to watch

  • Whether subscribers return to quarter-on-quarter growth in Q1 2027 (peak weight-loss season and the listing of Eli Lilly's Zepbound and Foundayo)
  • Whether gross margin holds above 57%
  • FDA peptide rules, expected to be clear within weeks
  • The target of an annualised overseas revenue run rate of more than $1 billion in 2027
  • When management gives a timetable for gross margin recovery

Risks

  • A fall of 100,000 subscribers quarter on quarter hits the premise behind the moat (users plus accumulated health data)
  • Gross margin has fallen from 74% to 57% with no recovery timetable
  • Operating cash flow fell from $149 million to $65.4 million, and is mainly propped up by payables
  • Huberman's related-party transactions weaken board independence
  • Goodwill has jumped from $278 million to $1.11 billion, which raises acquisition risk
Show 2 more
  • Convertible bonds of $1.37 billion plus $563 million of acquisition payments due put pressure on the balance sheet
  • Q4 revenue guidance is roughly flat quarter on quarter, a clear slowdown in growth

Sources 3

  1. SEC 8-K, Q3 results release (9 Nov)
  2. Q3 earnings call (9 Nov)
  3. SEC 8-K, Huberman appointment (9 Nov)